New Therapies for Ovarian Cancer

被引：10

作者：

Armstrong, Deborah K. ^{[1
]}

机构：

[1] Johns Hopkins, Sidney Kimmel Comprehens Canc Ctr, Skip Viragh Outpatient Canc Bldg, Baltimore, MD 21287 USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2018年 / 16卷 / 05期

关键词：

MAINTENANCE THERAPY; OPEN-LABEL; OLAPARIB; MULTICENTER; CARCINOMA; PHASE-2;

D O I：

10.6004/jnccn.2018.0034

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

In the latest NCCN Guidelines for Ovarian Cancer, the histologic subtypes of ovarian cancer are described in more depth as they vary by frequency, typical age and disease stage at presentation, treatment recommendations, and survival probabilities. The less common subtypes are also discussed. The update with the greatest impact on the treatment of ovarian cancer, however, is probably the use of maintenance therapy with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors, and 3 PARP inhibitors are now included in the guidelines. These drugs have made a large difference in outcome, both for patients with BRCA mutations and in unselected patients.

引用

页码：632 / 635

页数：4

共 5 条

[1] Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy [J].

Domchek, Susan M. ;

Aghajanian, Carol ;

Shapira-Frommer, Ronnie ;

Schmutzler, Rita K. ;

Audeh, M. William ;

Friedlander, Michael ;

Balmana, Judith ;

Mitchell, Gillian ;

Fried, Georgeta ;

Stemmer, Salomon M. ;

Hubert, Ayala ;

Rosengarten, Ora ;

Loman, Niklas ;

Robertson, Jane D. ;

Mann, Helen ;

Kaufman, Bella .

GYNECOLOGIC ONCOLOGY, 2016, 140 (02) :199-203

[2] Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study [J].

Gelmon, Karen A. ;

Tischkowitz, Marc ;

Mackay, Helen ;

Swenerton, Kenneth ;

Robidoux, Andre ;

Tonkin, Katia ;

Hirte, Hal ;

Huntsman, David ;

Clemons, Mark ;

Gilks, Blake ;

Yerushalmi, Rinat ;

Macpherson, Euan ;

Carmichael, James ;

Oza, Amit .

LANCET ONCOLOGY, 2011, 12 (09) :852-861

[3] Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer [J].

Ledermann, Jonathan ;

Harter, Philipp ;

Gourley, Charlie ;

Friedlander, Michael ;

Vergote, Ignace ;

Rustin, Gordon ;

Scott, Clare ;

Meier, Werner ;

Shapira-Frommer, Ronnie ;

Safra, Tamar ;

Matei, Daniela ;

Macpherson, Euan ;

Watkins, Claire ;

Carmichael, James ;

Matulonis, Ursula .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (15) :1382-1392

[4] Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer [J].

Mirza, M. R. ;

Monk, B. J. ;

Herrstedt, J. ;

Oza, A. M. ;

Mahner, S. ;

Redondo, A. ;

Fabbro, M. ;

Ledermann, J. A. ;

Lorusso, D. ;

Vergote, I. ;

Ben-Baruch, N. E. ;

Marth, C. ;

Madry, R. ;

Christensen, R. D. ;

Berek, J. S. ;

Dorum, A. ;

Tinker, A. V. ;

du Bois, A. ;

Gonzalez-Martin, A. ;

Follana, P. ;

Benigno, B. ;

Rosenberg, P. ;

Gilbert, L. ;

Rimel, B. J. ;

Buscema, J. ;

Balser, J. P. ;

Agarwal, S. ;

Matulonis, U. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (22) :2154-2164

[5]

Swisher EM, 2017, LANCET ONCOL, V18, P75, DOI [10.1016/S1470-2045(16)30559-9, 10.1016/s1470-2045(16)30559-9]

← 1 →